Skip to content

Express Gratitude

Opportunity

Clinical trial participants and their care partners often do not feel valued for their contribution to clinical trials, which may impact retention, participant satisfaction, and overall adherence. Receiving an act of appreciation (e.g., a thank you card / letter) during a clinical trial is directly related to overall satisfaction with the clinical trial.

Considerations to Help Action the Opportunity

  • Include decisions around gratitude as part of the engagement strategy early in the clinical development planning process
  • Understand which tools and templates are most appropriate to your study and patient population 
  • Test gratitude tools with the patient population
  • Define distribution methods and understand how use of decentralized trials / platforms may impact which format is used
  • Identify opportunities to evaluate the value of the tactics and how they were received by participants / care partners (e.g., incorporating questions regarding gratitude into the SPFQ or similar patient feedback questionnaire)

Value and Potential Benefits

  • Improves recruitment from word-of-mouth referrals by participants speaking positively about their experience in clinical trials 
  • Improves engagement, adherence, and compliance by recognizing the time and effort participants contribute to the clinical trial 
  • Increases participant’s satisfaction and perceived value of their clinical trial journey by recognizing the value of their experience
  • Improves relationships with clinical research staff by recognizing the important relationship they develop with the patient and work needed to make the trial successful at their site
  • Improves industry reputation and trust in clinical research 

Related Blog Posts

A New Era in Advancing Care for Pregnant and Breastfeeding Patients

One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations  (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…

Improving Medicine Use During Pregnancy & Breastfeeding: Forging a Path Forward   

The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…

Transforming Pharmacovigilance: Solutions to Solve Regulatory Challenges

Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…